Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease
New financing will help Moonwalk Biosciences expand its pipeline of siRNA medicines targeting adipose tissue while building out its proprietary drug discovery platform. The post Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease appeared first on GEN - Genetic Engineering and Biotechnology News .
We haven't written up this one. GEN Biotechnology has the full story — the link below goes straight to it.
